5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model

Neurobiology of Disease

Volumn 60, Issue , 2013, Pages 108-114

  Tronci, Elisabetta ^a   Lisci, Carlo ^a   Stancampiano, Roberto ^a   Fidalgo, Camino ^a   Collu, Maria ^a   Devoto, Paola ^a   Carta, Manolo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

5 hydroxy tryptophan; Dopamine; Dyskinesia; L DOPA; Serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; DOPAMINE; ELTOPRAZINE; LEVODOPA; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; EXPERIMENTAL RAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

5-HTP; 5-HYDROXY-TRYPTOPHAN; 6-HYDROXY-DOPAMINE; 6-OHDA; ABNORMAL INVOLUNTARY MOVEMENTS; AIMS; DA; DOPAMINE; DYSKINESIA; L-DOPA; L-DOPA-INDUCED DYSKINESIA; LID; PARKINSON'S DISEASE; PD; SEROTONIN; SEROTONIN REUPTAKE INHIBITORS; SSRIS; TH; TYROSINE HYDROXYLASE;

5-HYDROXYTRYPTOPHAN; ADRENERGIC AGENTS; ANIMALS; CAUDATE NUCLEUS; DISEASE MODELS, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 84884715553     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.08.014     Document Type: Article

References (39)

1. Barone P. Treatment of depressive symptoms in Parkinson's disease. Eur. J. Neurol. 2011, 18:11-15.
2. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013, 28:1088-1096.
3. Birdsall T.C. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern. Med. Rev. 1998, 3:271-280.
4. Bishop C., Krolewski D.M., Eskow K.L., Barnum C.J., Dupre K.B., Deak T., Walker P.D. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 2009, 87:1645-1658.
5. Carta M., Bezard E. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 2011, 198:245-251.
6. Carta M., Fadda F., Stancampiano R. Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine. Brain Res. 2006, 1094:86-91.
7. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
8. Casanovas J.M., Hervás I., Artigas F. Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999, 14:1441-1445.
9. Ceci A., Baschirotto A., Borsini F. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 1994, 33:709-713.
10. Choi C., Sohn Y.H., Lee J.H., Kim J. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease. J. Neurol. Sci. 2000, 172:12-16.
11. Cummings J.L., Masterman D.L. Depression in patients with Parkinson's disease. Int. J. Geriatr. Psychiatry 1999, 14:711-718.
12. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
13. Devoto P., Flore G., Vacca G., Pira L., Arca A., Casu M.A., Pani L., Gessa G.L. Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology (Berl) 2003, 167:79-84.
14. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
15. Eskow Jaunarajs K.L., Angoa-Perez M., Kuhn D.M., Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci. Biobehav. Rev. 2011, 35:556-564.
16. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
17. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
18. Everett G.M., Borcherding J.W. L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970, 168:847-850.
19. Hajós M., Hajós-Korcsok E., Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br. J. Pharmacol. 1999, 126:1741-1750.
20. Jangid P., Malik P., Singh P., Sharma M., Gulia A.K. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J. Psychiatry 2013, 6:29-34.
21. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 2001, 21:2889-2896.
22. Lee C.S., Cenci M.A., Schulzer M., Björklund A. Embryonic ventral mes-encephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123:1365-1379.
23. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2012, 112:1456-1476.
24. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
25. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
26. Nahimi A., Høltzermann M., Landau A.M., Simonsen M., Jakobsen S., Alstrup A.K., Vang K., Møller A., Wegener G., Gjedde A., Doudet D.J. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J. Neurochem. 2012, 120:806-817.
27. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 2010, 38:136-143.
28. Nègre-Pagès L., Grandjean H., Lapeyre-Mestre M., Montastruc J.L., Fourrier A., Lépine J.P., Rascol O., DoPaMiP Study Group Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study. Mov. Disord. 2010, 25:157-166.
29. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
30. Perez-Lloret S., Rascol O. Parkinson disease: serotonin reuptake inhibitors for depression in PD. Nat. Rev. Neurol. 2012, 8:365-366.
31. Richard I.H., McDermott M.P., Kurlan R., Lyness J.M., Como P.G., Pearson N., Factor S.A., Juncos J., Serrano Ramos C., Brodsky M., Manning C., Marsh L., Shulman L., Fernandez H.H., Black K.J., Panisset M., Christine C.W., Jiang W., Singer C., Horn S., Pfeiffer R., Rottenberg D., Slevin J., Elmer L., Press D., Hyson H.C., McDonald W., SAD-PD Study Group A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78:1229-1236.
32. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
33. Sano I. l-5-Hydroxytryptophan-(l-5-HTP) therapy. Folia Psychiatr. Neurol. Jpn. 1972, 26:7-17.
34. Schallert T., Tillerson J. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimising behavioral assessment of outcome. Innovative Models of CNS Disease; From Molecule to Therapy 1999, 131-151. Human Press, Clifton, NJ.
35. Shaw K., Turner J., Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust. N. Z. J. Psychiatry 2002, 36:488-491.
36. Tronci E., Shin E., Björklund A., Carta M. Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci. Res. 2012, 73:168-172.
37. Turner E.H., Loftis J.M., Blackwell A.D. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Ther. 2006, 109:325-338.
38. Van Praag H.M. Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol. Bull. 1984, 20:599-602.
39. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2163-2168.